Silence Therapeutics (NASDAQ:SLN) Upgraded to "Hold" at Wall Street Zen

Wall Street Zen upgraded shares of Silence Therapeutics (NASDAQ:SLN - Free Report) from a sell rating to a hold rating in a report issued on Saturday morning.

A number of other research analysts have also recently commented on SLN. Chardan Capital reissued a "buy" rating and issued a $35.00 price target on shares of Silence Therapeutics in a report on Friday. HC Wainwright reissued a "buy" rating and issued a $75.00 price target on shares of Silence Therapeutics in a report on Friday. Morgan Stanley lowered their price target on Silence Therapeutics from $45.00 to $25.00 and set an "overweight" rating on the stock in a report on Friday, May 9th. BMO Capital Markets lowered their price target on Silence Therapeutics from $67.00 to $25.00 and set an "outperform" rating on the stock in a report on Tuesday, March 4th. Finally, The Goldman Sachs Group decreased their price objective on Silence Therapeutics from $4.00 to $3.00 and set a "sell" rating on the stock in a report on Friday, May 9th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, Silence Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $33.83.

Silence Therapeutics Price Performance

Shares of SLN stock traded down $0.26 during trading hours on Friday, reaching $5.33. 77,781 shares of the company traded hands, compared to its average volume of 303,932. Silence Therapeutics has a 12-month low of $1.97 and a 12-month high of $22.47. The company has a market cap of $159.53 million, a P/E ratio of -3.39 and a beta of 1.41. The firm has a 50-day moving average price of $4.13 and a 200 day moving average price of $4.95.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.60) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.42). Silence Therapeutics had a negative net margin of 342.00% and a negative return on equity of 62.81%. The company had revenue of $0.14 million for the quarter, compared to analysts' expectations of $3.58 million. Sell-side analysts predict that Silence Therapeutics will post -1.77 EPS for the current year.

Institutional Trading of Silence Therapeutics

Several hedge funds have recently modified their holdings of SLN. JPMorgan Chase & Co. purchased a new stake in shares of Silence Therapeutics during the 4th quarter worth approximately $26,000. Barclays PLC increased its position in shares of Silence Therapeutics by 83.8% during the 4th quarter. Barclays PLC now owns 6,126 shares of the company's stock valued at $42,000 after purchasing an additional 2,793 shares during the last quarter. Virtus ETF Advisers LLC increased its position in shares of Silence Therapeutics by 130.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company's stock valued at $74,000 after purchasing an additional 6,098 shares during the last quarter. Jump Financial LLC bought a new position in shares of Silence Therapeutics during the 1st quarter valued at approximately $74,000. Finally, Ameriprise Financial Inc. bought a new position in shares of Silence Therapeutics during the 4th quarter valued at approximately $113,000. 98.73% of the stock is owned by hedge funds and other institutional investors.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.